Business Wire

WA-KYMETA

Share
Kymeta Interoperability with Kepler LEO Satellites Promises Powerful Connectivity of the Future with Kymeta™ u8 Terminal

Kymeta (www.kymetacorp.com ), the communications company making mobile global, and Kepler Communications (www.kepler.space ) announced today the successful demonstration of the Kymeta u8 Terminal with LEO satellite acquisition , tracking and throughput measurements, during extreme cold weather temperatures. The collaboration with Kepler supports Kymeta’s goal to develop solutions that are future proof with a clear LEO upgrade path and compatible with growing mega constellations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323005226/en/

In 2020, Kepler was selected for an extended u8 beta trial to capture the extended Northern winter in Inuvik, Canada. Frequent revisit times from the Kepler LEO satellites combined with the local environment of unprotected cold weather, snow, and ice provided a unique testing opportunity for the latest Kymeta technology. Results have demonstrated a significant increase in performance with lower latency, enhanced look angles and speeds that are approaching 10X faster than earlier products with higher throughput and total data passed.

The u8 system is designed to work down to -40o C. During testing, Kymeta and Kepler were able to update software facilitating the testing of new algorithms in real time. Updates included capabilities of on-board FPGA-based tracking receivers, which allowed for usage of channels more than 2 times larger than previous demonstrations.

Testing results exceeded expectations during these cold weather trials with average uplink and downlink speeds of 100 Mbps, providing the ability to transfer more than two gigabytes of data with each pass. Initial testing was completed using linear polarization on the u8 – in a future software upgrade the addition of circular polarization support will lead to additional increases in data transfer speeds.

“Kepler has been a great trial partner because they are agile and able to make adjustments for optimized performance at the same time we are adjusting the u8 terminal,” said David Harrower, Senior Vice President of Global Sales at Kymeta. “Many of our customers are interested in compatibility with LEO satellite services, and this testing helps ensure the longevity of the u8 and Kymeta Connect as well as offer a solution that takes advantage of the increased utility of LEO satellites.”

"The performance of the Kymeta u8 with Kepler's Global Data Service has exceeded our expectations," said Wen Cheng Chong, Kepler's CTO and Co-Founder. "Our recent testing and development efforts demonstrated not only the ability to move many more gigabytes of data than expected with each pass, but also the u8's ability to operate in polar environments, where many of Kepler's early adopters operate. With Kepler's recently increased capacity the u8 can serve customers globally, pole-to-pole and all points in between."

In January, Kepler launched 8 new satellites via SpaceX’s first dedicated SmallSat Rideshare Program. On March 22nd , Kepler launched an additional two satellites via the Soyuz-2, expanding its active constellation to 15 satellites in total. An additional launch is planned for June. Kymeta believes the collaboration with Kepler and further testing is instrumental to providing reliable connectivity and superior benefits to customers.

Kymeta next-generation solutions are built for mobility and designed specifically for the needs of global defense agencies, government, public safety, and commercial customers. Through the launch of the u8 and Kymeta Connect, the company has meaningfully increased antenna throughput and reduced the total cost of ownership. Its products offer a breakthrough in performance, ease of use, and hybrid satellite-cellular connectivity services.

About Kymeta

Kymeta is unlocking the potential of broadband satellite connectivity, combined with cellular networks, to satisfy the overwhelming demand for comms on the move and making mobile global. Lepton Global Solutions, a Kymeta company, hosts the company’s satellite connectivity solutions and offers unique, complete, and turnkey bundled solutions to the market based on best-in-class technologies and tailored customer-centric services that meet and exceed customer mission requirements. These solutions in tandem with the company’s flat-panel satellite antenna, the first of its kind, and Kymeta Connect™ services provide revolutionary mobile connectivity on satellite and hybrid satellite-cellular networks to customers around the world. Backed by U.S. and international patents and licenses, the Kymeta terminal addresses the need for lightweight, slim, and high-throughput communication systems that do not require mechanical components to steer toward a satellite. Kymeta makes connecting easy – for any vehicle, vessel, or fixed platform.

Kymeta is a privately held company based in Redmond, Washington.

For more information, visit kymetacorp.com .

About Kepler Communications Inc.

Kepler is a satellite telecommunications provider based in Canada, backed by Costanoa Ventures, IA Ventures and other leading investors. Kepler’s mission is to connect people and things Everywhere, on earth and beyond. To this end, Kepler will build an in-space telecommunications network through an incremental deployment of products and technologies. The first to launch and operate a Ku-band satellite service in Low Earth Orbit, Kepler has expanded its capabilities with the successful commissioning of a cubesat production facility at their Toronto headquarters, from which the GEN 1 satellites are being delivered.

For more information, visit www.kepler.space and @KeplerComms.

Link:

ClickThru

Social Media:

https://www.facebook.com/kymetacorp

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye